MedPath

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

Phase 3
Completed
Conditions
Asthma
Interventions
Registration Number
NCT03015259
Lead Sponsor
Kindeva Drug Delivery
Brief Summary

A randomized multiple-dose, placebo-controlled, parallel group design consisting of a 2-week run-in period followed by a 6-week treatment period of the placebo, Test product (Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5 mcg), or Reference product Symbicort® inhalation aerosol.

Detailed Description

This is a pivotal trial that will examine therapeutic equivalence of a new generic fixed-dose combination product containing Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5 mcg and reference listed drug (RLD) Symbicort® inhalation aerosol in adult patients with chronic but stable asthma as defined in National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP 3) guidelines. To ensure adequate study sensitivity the test and reference products should both be statistically superior to placebo (p\<0.05) with regard to the bioequivalent study primary endpoints.

A secondary study objective is the safety and tolerability of the test compound.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1762
Inclusion Criteria
  • Adult male or female subjects of non-childbearing or of childbearing potential committed to consistent and correct use of an acceptable method of birth control
  • Diagnosed with asthma, as defined by the National Asthma Education and Prevention Program (NAEPP),at least 6 months prior to screening
  • Moderate-to-severe asthma with a pre-bronchodilator FEV1 of >45% and <85% of predicted normal, measured at least 6 hours after short-acting β agonist (SABA)and at least 24 hours after the last dose of long-acting β agonist (LABA), at the screening visit and on the day of treatment
  • >15% and >0.20 L reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI)
  • Patients should be stable on their chronic asthma treatment regimen for at least 4 weeks prior to enrollment
  • Currently non-smoking; having not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and having < 10 pack-years of historical use
  • Able to replace current regularly scheduled short-acting β agonists (SABAs) with salbutamol/albuterol inhaler for use only on an as-needed basis for the duration of the study (subjects should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits)
  • Willing to discontinue their asthma medications (inhaled corticosteroids and long-acting β agonists) during the run-in period and for the remainder of the study
  • Willingness to give their written informed consent to participate in the study
Exclusion Criteria
  • Life-threatening asthma, defined as a history of asthma episodes(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma-related syncopal episodes(s), or hospitalizations within the past year or during the run-in period
  • Significant respiratory disease other than asthma (chronic obstructive pulmonary disease (COPD), interstitial lung disease, etc.)
  • Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that, in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbated during the study
  • Patients who required systemic corticosteroids (for any reason) within the past 4 weeks
  • Hypersensitivity to any sympathomimetic drug (e.g., formoterol or albuterol) or any inhaled, intranasal, or systemic corticosteroid therapy
  • Patients currently receiving β-blockers

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Treatment 1Budesonide/Formoterol fumarate dihydrateGeneric Budesonide/Formoterol Fumarate Dihydrate (80mcg/4.5mcg) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
Treatment 3PlaceboPlacebo Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
Treatment 2SymbicortSymbicort (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
Primary Outcome Measures
NameTimeMethod
Area Under the Serial Forced Expiratory Volume in 1 Second (FEV1)Day 1

FEV1 Area calculated over 12 hours (measurements at 0, 1, 2, 3, 4, 6, 8, 12 hours post-dose) on Day 1 of treatment. Because this was a primary endpoint, Per Protocol Population used to calculate this endpoint.

Change From Baseline in FEV1 Measured in the Morning at the End of Treatment VisitDay 1 - Day 49

Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42 (+/- 7 days). Baseline was defined as the average of 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: \[FEV1 at end of treatment\] - \[Baseline FEV1\].

Secondary Outcome Measures
NameTimeMethod
Number of Participants With Adverse Events6 Weeks

Number of participants reporting at least one adverse event (safety population)

Trial Locations

Locations (93)

Clinical Research Consortuim Arizona

🇺🇸

Tempe, Arizona, United States

Anaheim Clinical Trials LLC

🇺🇸

Anaheim, California, United States

Allergy and Asthma Specialists Medical Group

🇺🇸

Huntington Beach, California, United States

Integrated Research Group Inc

🇺🇸

Riverside, California, United States

Warren W Pleskow MD

🇺🇸

Encinitas, California, United States

Allainz Research Institute Inc

🇺🇸

Westminster, California, United States

Allergy and Asthma Associates of Southern California, A Medical Group, Inc.

🇺🇸

Mission Viejo, California, United States

Allergy and Asthma Associates of Northern California

🇺🇸

San Jose, California, United States

Allergy & Asthma Clinical Research

🇺🇸

Walnut Creek, California, United States

Western States Clinical Research Inc

🇺🇸

Arvada, Colorado, United States

Asthma and Allergy Associates PC

🇺🇸

Colorado Springs, Colorado, United States

Rocky Mountain Center for Clinical Research

🇺🇸

Wheat Ridge, Colorado, United States

Innovative Clinical Research Inc

🇺🇸

Lafayette, Colorado, United States

Innovative Research of West Florida

🇺🇸

Largo, Florida, United States

Saint Francis Sleep Allergy and Lung Institute

🇺🇸

Clearwater, Florida, United States

Emerald Coast Research Associates

🇺🇸

Panama City, Florida, United States

Advanced Research Institute Inc

🇺🇸

New Port Richey, Florida, United States

Allergy and Asthma Dtc

🇺🇸

Tallahassee, Florida, United States

Asthma and Allergy Center of Chicago Sc

🇺🇸

River Forest, Illinois, United States

Genesis Clinical Research and Consulting LLC

🇺🇸

Fall River, Massachusetts, United States

Chesapeake Clinical Research Inc

🇺🇸

Baltimore, Maryland, United States

Infinity Medical Research LLC

🇺🇸

North Dartmouth, Massachusetts, United States

Northeast Medical Research Associates Inc

🇺🇸

North Dartmouth, Massachusetts, United States

Clinical Research of the Ozarks INC

🇺🇸

Columbia, Missouri, United States

Clinical Research of the Ozarks Inc

🇺🇸

Rolla, Missouri, United States

Midwest Clinical Research LLC

🇺🇸

Saint Louis, Missouri, United States

The Clinical Research Center LLC

🇺🇸

Saint Louis, Missouri, United States

Montana Medical Research

🇺🇸

Missoula, Montana, United States

The Asthma and Allergy Center PC

🇺🇸

Bellevue, Nebraska, United States

Pioneer Clinical Research LLC

🇺🇸

Bellevue, Nebraska, United States

Ocean Allergy & Respiratory Research Center

🇺🇸

Brick, New Jersey, United States

Atlantic Research Center LLC

🇺🇸

Ocean Township, New Jersey, United States

Princeton Center For Clinical Research

🇺🇸

Skillman, New Jersey, United States

Allergy Partners of Western North Carolina

🇺🇸

Asheville, North Carolina, United States

North Carolina Clinical Research

🇺🇸

Raleigh, North Carolina, United States

Rapha Institute for Clinical Research

🇺🇸

Fayetteville, North Carolina, United States

Empirical Medical Research

🇺🇸

Canton, Ohio, United States

Toledo Center For Clinical Research

🇺🇸

Sylvania, Ohio, United States

Toledo Institute of Clinical Research

🇺🇸

Toledo, Ohio, United States

OK Clinical Research, LLC

🇺🇸

Edmond, Oklahoma, United States

Oklahoma Institute of Allergy and Asthma Clinical Research LLC

🇺🇸

Edmond, Oklahoma, United States

Allergy and Asthma Research Group

🇺🇸

Eugene, Oregon, United States

Vital Prospects Clinical Research Institute PC

🇺🇸

Tulsa, Oklahoma, United States

Clinical Research Institute of Southern Oregon PC

🇺🇸

Medford, Oregon, United States

Clinical Trial Center LLC

🇺🇸

Jenkintown, Pennsylvania, United States

Montgomery Medical Inc

🇺🇸

Smithfield, Pennsylvania, United States

Asthma & Allergy Physicians of Rhode Island Clinical Research Institute

🇺🇸

Warwick, Rhode Island, United States

S. Carolina Pharmaceutical Research

🇺🇸

Spartanburg, South Carolina, United States

National Allergy and Asthma Research, LLC

🇺🇸

North Charleston, South Carolina, United States

Pharmaceutical Research & Consulting Inc

🇺🇸

Dallas, Texas, United States

AARA Research Center

🇺🇸

Dallas, Texas, United States

Western Sky Medical Research

🇺🇸

El Paso, Texas, United States

Metroplex Pulmonology & Sleep Center

🇺🇸

McKinney, Texas, United States

Central Texas Health Research Corporation

🇺🇸

New Braunfels, Texas, United States

Allergy Asthma Research Institute

🇺🇸

Waco, Texas, United States

National Clinical Resources Inc

🇺🇸

Provo, Utah, United States

Clinical Research Partners LLC

🇺🇸

Henrico, Virginia, United States

Marycliff Allergy Specialists PS

🇺🇸

Spokane, Washington, United States

Allergy Asthma and Sinus Center

🇺🇸

Greenfield, Wisconsin, United States

California Allergy and Asthma Medical Group Inc

🇺🇸

Los Angeles, California, United States

Jonathan Corren MD, Inc.

🇺🇸

Los Angeles, California, United States

Southern California Institute For Respiratory Diseases, Inc.

🇺🇸

Los Angeles, California, United States

Pioneer Research Solutions

🇺🇸

Houston, Texas, United States

San Marcus Research Clinic Inc

🇺🇸

Miami, Florida, United States

Prestige Clinical Research Center Inc

🇺🇸

Miami, Florida, United States

Research Institute of South Florida Inc

🇺🇸

Miami, Florida, United States

Clintex Research Group, Inc

🇺🇸

Miami, Florida, United States

Suncoast Research Group LLC

🇺🇸

Miami, Florida, United States

Applemed Research Inc

🇺🇸

Miami, Florida, United States

Biotech Pharmaceutical Group, LLC

🇺🇸

Miami, Florida, United States

Clinical Research Consortium Nevada

🇺🇸

Las Vegas, Nevada, United States

Quality Assurance Research Center

🇺🇸

San Antonio, Texas, United States

Sylvana Research Associates

🇺🇸

San Antonio, Texas, United States

Bernstein Clinical Research Center Inc

🇺🇸

Cincinnati, Ohio, United States

Clinical Research Institute, Inc.

🇺🇸

Minneapolis, Minnesota, United States

New Horizons Clinical Research

🇺🇸

Cincinnati, Ohio, United States

Allergy and Asthma Research Center PA

🇺🇸

San Antonio, Texas, United States

Analab Clinical Research Inc

🇺🇸

Lenexa, Kansas, United States

Paul Shapero's Private Practice

🇺🇸

Bangor, Maine, United States

ADAC Research

🇺🇸

Greenville, South Carolina, United States

Little Rock Allergy and Asthma Clinical Research Center

🇺🇸

Little Rock, Arkansas, United States

Allied Clinical Research LLC

🇺🇸

Reno, Nevada, United States

Spartanburg Medical Research

🇺🇸

Spartanburg, South Carolina, United States

Timber Lane Allergy and Asthma Research LLC

🇺🇸

South Burlington, Vermont, United States

New Phase Research & Development

🇺🇸

Knoxville, Tennessee, United States

Clinical Research Center of Alabama LLC

🇺🇸

Birmingham, Alabama, United States

Elite Clinical Studies

🇺🇸

Phoenix, Arizona, United States

Colorado Allergy and Asthma Centers PC

🇺🇸

Denver, Colorado, United States

Bethesda Allergy Asthma and Research Center LLC

🇺🇸

Bethesda, Maryland, United States

Santiago Reyes, MD

🇺🇸

Oklahoma City, Oklahoma, United States

Allergy Associates Research Center LLC

🇺🇸

Portland, Oregon, United States

IMMUNOe Research Centers

🇺🇸

Centennial, Colorado, United States

Southeastern Integrated Medical

🇺🇸

Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath